Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
bioAffinity Technologies, Inc. (BIAF)
NASDAQ:BIAF
RESEARCH TOOLSreports
Holding BIAF?
Track your performance easily
BIAF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.20 - $3.62
Previous Close$1.24
Volume66.24K
Average Volume (3M)122.63K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)$800.00K
Total Debt (Recent Filing)$1.72M
Price to Earnings (P/E)―
Beta2.47
Next Earnings
Mar 28, 2025EPS Estimate
-$0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.80
Shares Outstanding15,584,635
10 Day Avg. Volume85,733
30 Day Avg. Volume122,629
Standard Deviation0.26
R-Squared0.22
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)6.35
Price to Sales (P/S)2.21
Price to Cash Flow (P/CF)-3.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$6.00Price Target Upside391.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
bioAffinity Technologies, Inc. News
PremiumCompany Announcements
bioAffinity Technologies Reports Strong Q3 Growth
PremiumPre-Earnings
Is BIAF a Buy, Before Earnings?
Ownership Overview
29.22% Insiders
1.56% Mutual Funds
0.13% Other Institutional Investors
67.41% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
BIAF FAQ
What was bioAffinity Technologies, Inc.’s price range in the past 12 months?
bioAffinity Technologies, Inc. lowest stock price was $1.20 and its highest was $3.62 in the past 12 months.
What is bioAffinity Technologies, Inc.’s market cap?
Currently, no data Available
When is bioAffinity Technologies, Inc.’s upcoming earnings report date?
bioAffinity Technologies, Inc.’s upcoming earnings report date is Mar 28, 2025 which is in 126 days.
How were bioAffinity Technologies, Inc.’s earnings last quarter?
bioAffinity Technologies, Inc. released its earnings results on Nov 14, 2024. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.15 by -$0.01.
Is bioAffinity Technologies, Inc. overvalued?
According to Wall Street analysts bioAffinity Technologies, Inc.’s price is currently Undervalued.
Does bioAffinity Technologies, Inc. pay dividends?
bioAffinity Technologies, Inc. does not currently pay dividends.
What is bioAffinity Technologies, Inc.’s EPS estimate?
bioAffinity Technologies, Inc.’s EPS estimate is -$0.14.
How many shares outstanding does bioAffinity Technologies, Inc. have?
bioAffinity Technologies, Inc. has 15,584,635 shares outstanding.
What happened to bioAffinity Technologies, Inc.’s price movement after its last earnings report?
bioAffinity Technologies, Inc. reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.15. Following the earnings report the stock price went up 3.101%.
Which hedge fund is a major shareholder of bioAffinity Technologies, Inc.?
Among the largest hedge funds holding bioAffinity Technologies, Inc.’s share is Sheaff Brock Investment Advisors LLC. It holds bioAffinity Technologies, Inc.’s shares valued at 42K.
---
bioAffinity Technologies, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (391.80% Upside)
$6.00 (391.80% Upside)
Hedge Fund Trend
Increased
By 5.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 9.0%
Last 30 Days ▼ 9.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.41%
12-Months-Change
Fundamentals
Return on Equity
-167.00%
Trailing 12-Months
Asset Growth
-35.70%
Trailing 12-Months
Company Description
bioAffinity Technologies, Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company is involved in developing technologies that, in the future, will be able to detect and monitor diseases of the lung and other cancers and treat many cancers.
---
BIAF Earnings Call
Q4 2023
0:00 / 0:00
---
BIAF Stock 12 Month Forecast
Average Price Target
$6.00
▲(391.80% Upside)
Technical Analysis
Brainstorm Cell Therapeutics
―
Cellectar Biosciences
―
Fate Therapeutics
―
ADMA Biologics
―
Best Analysts Covering BIAF
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-40.30%
reiterated a buy rating 3 days ago
Copying Anthony Vendetti's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -40.30% per trade.
---